These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 1280331

  • 1. Ornithine decarboxylase activity is critical for cell transformation.
    Auvinen M, Paasinen A, Andersson LC, Hölttä E.
    Nature; 1992 Nov 26; 360(6402):355-8. PubMed ID: 1280331
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Transformation of NIH/3T3 cells by ornithine decarboxylase overexpression.
    Moshier JA, Dosescu J, Skunca M, Luk GD.
    Cancer Res; 1993 Jun 01; 53(11):2618-22. PubMed ID: 8495425
    [Abstract] [Full Text] [Related]

  • 4. Transforming growth factor beta 1 selectively regulates ornithine decarboxylase gene expression in malignant H-ras transformed fibrosarcoma cell lines.
    Hurta RA, Greenberg AH, Wright JA.
    J Cell Physiol; 1993 Aug 01; 156(2):272-9. PubMed ID: 8344985
    [Abstract] [Full Text] [Related]

  • 5. Cloning and characterization of a thermolabile v-src gene for use in reversible transformation of mammalian cells.
    Maroney AC, Qureshi SA, Foster DA, Brugge JS.
    Oncogene; 1992 Jun 01; 7(6):1207-14. PubMed ID: 1375718
    [Abstract] [Full Text] [Related]

  • 6. Effects of overexpression of ornithine decarboxylase (ODC) on growth control and oncogene-induced cell transformation.
    Hibshoosh H, Johnson M, Weinstein IB.
    Oncogene; 1991 May 01; 6(5):739-43. PubMed ID: 1711188
    [Abstract] [Full Text] [Related]

  • 7. Overexpression of antizyme-inhibitor in NIH3T3 fibroblasts provides growth advantage through neutralization of antizyme functions.
    Keren-Paz A, Bercovich Z, Porat Z, Erez O, Brener O, Kahana C.
    Oncogene; 2006 Aug 24; 25(37):5163-72. PubMed ID: 16568078
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Overproduction of ornithine decarboxylase caused by relief of translational repression is associated with neoplastic transformation.
    Shantz LM, Pegg AE.
    Cancer Res; 1994 May 01; 54(9):2313-6. PubMed ID: 8162572
    [Abstract] [Full Text] [Related]

  • 10. Ornithine decarboxylase induction in transformation by H-Ras and RhoA.
    Shantz LM, Pegg AE.
    Cancer Res; 1998 Jul 01; 58(13):2748-53. PubMed ID: 9661886
    [Abstract] [Full Text] [Related]

  • 11. Tumor promoter-induced ornithine decarboxylase gene expression occurs independently of AP-1 activation.
    Jansen AP, Colburn NH, Verma AK.
    Oncogene; 1999 Oct 14; 18(42):5806-13. PubMed ID: 10523861
    [Abstract] [Full Text] [Related]

  • 12. Molecular cloning and functional analysis of a novel cadmium-responsive proto-oncogene.
    Joseph P, Lei YX, Whong WZ, Ong TM.
    Cancer Res; 2002 Feb 01; 62(3):703-7. PubMed ID: 11830523
    [Abstract] [Full Text] [Related]

  • 13. Most of the substrates of oncogenic viral tyrosine protein kinases can be phosphorylated by cellular tyrosine protein kinases in normal cells.
    Kamps MP, Sefton BM.
    Oncogene Res; 1988 Sep 01; 3(2):105-15. PubMed ID: 2465525
    [Abstract] [Full Text] [Related]

  • 14. Expression of human chromosome 2 ornithine decarboxylase gene in ornithine decarboxylase-deficient Chinese hamster ovary cells.
    Hsieh JT, Denning MF, Heidel SM, Verma AK.
    Cancer Res; 1990 Apr 15; 50(8):2239-44. PubMed ID: 2317811
    [Abstract] [Full Text] [Related]

  • 15. Expression of an ornithine decarboxylase dominant-negative mutant reverses eukaryotic initiation factor 4E-induced cell transformation.
    Shantz LM, Coleman CS, Pegg AE.
    Cancer Res; 1996 Nov 15; 56(22):5136-40. PubMed ID: 8912847
    [Abstract] [Full Text] [Related]

  • 16. Morphological transformation, tumorigenicity and src-specific cytotoxic T-lymphocyte-mediated tumor immunity induced by murine 3T3 cells expressing src oncogenes encoding novel non-myristylated N-terminal domains.
    Gelman IH, Khan S, Hanafusa H.
    Oncogene; 1993 Nov 15; 8(11):2995-3004. PubMed ID: 7692370
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Transformation of NIH3T3 cells by Rous sarcoma virus occurs with high efficiency in the absence of proviral rearrangements or amplification.
    Falcone G, Provenzano C, Alemà S, Tatò F.
    Oncogene; 1992 Oct 15; 7(10):1913-20. PubMed ID: 1328985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.